Al Hammadi Company For Development And Investment
- Company typePublic
- Founded1985
- HeadquartersRiyadh, Saudi Arabia
- Headcount1,001–5,000
- GTM typeB2B and B2C
- OfferingServices
Al Hammadi Company For Development And Investment firmographics
Firmographics- Name
- Al Hammadi Company For Development And Investment
- Legal name
- Al Hammadi Holding Company
- Website
- https://alhammadi.com
- Company type
- Public
- Founded year
- 1985
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Al Hammadi Company For Development And Investment industry classification
Industry- Product category
- Hospital and Healthcare Services
- NAICS
- General Medical and Surgical Hospitals (6221)
- SIC
- Services-Hospitals (8060), Services-Home Health Care Services (8082), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Private/For-Profit Hospital Systems (HLAFAAAF)
Keywords
Where Al Hammadi Company For Development And Investment is headquartered
LocationHeadquarters
- HQ city
- Riyadh
- HQ country
- Saudi Arabia
- HQ region
- Middle East
Offices1 record
Markets served
Al Hammadi Company For Development And Investment business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure, Technology or R&D, Others
Revenue model
- Hospital / Medical Services: Primary revenue from two operating hospitals in Riyadh offering inpatient (600 rooms) and outpatient (180 clinics) services. Revenue split includes MOH patients, private insurance patients, and direct-pay patients. The Medical Services segment is the largest contributor, with 2026 Q1 revenues of SAR 246.94 million. Segment revenue grew 2.6% YoY in Q1 2026.
- Pharmaceutical Products: Revenue from pharmaceutical distribution through Pharmaceutical Services Company subsidiary, and retail pharmacy sales. The pharmaceutical segment showed 17.7% YoY growth to SAR 72.15 million in Q1 2026, driven by increased retail sales through the company's subsidiary.
- Medical Support Services: Revenue from subsidiaries including Arabian Hospitality (hygiene, laundry, food services), Unified Procurement (hospital supplies management), and Construction & Maintenance services.
- Training & Education Services: Revenue from Support Services Institutes for Training (acquired 100% of Najd Training Institutes in 2020), providing vocational and professional training programs.
- Sports Medicine Partnership (A.C. Milan): Revenue from SAR 54.5 million multi-year strategic cooperation agreement with A.C. Milan as Official Medical & Rehabilitation Partner in KSA, spanning 8 years through June 2033. The agreement provides medical, rehabilitation and performance-related services.
Go-to-market motion1 record
Distribution channels6 records
Marketing channels6 records
Al Hammadi Company For Development And Investment product offering
Product offeringCore offering
Al Hammadi Holding operates an integrated healthcare group headquartered in Riyadh, Saudi Arabia, delivering world-class inpatient and outpatient hospital services through its Al Hammadi Hospitals Group (Al Suwaidi and Al Nuzha hospitals, with Al Olaya under renovation and Al Narjis planned). The group also distributes pharmaceuticals, provides home medical care, telemedicine, medical training, hospital support services, and biopharma R&D across wholly-owned and affiliated subsidiaries.
Product overview
Al Hammadi Holding is an integrated healthcare group and premier hospital operator in Riyadh, Saudi Arabia, operating as a diversified healthcare ecosystem. The company operates through its core hospital network (Al Hammadi Hospital Group comprising Al Suwaidi, Al Nuzha, Al Olaya, and upcoming Al Narjis facilities) alongside multiple subsidiaries and affiliates covering the full healthcare value chain. Key subsidiaries include Pharmaceutical Services, Sudair Pharmaceutical (35% stake), Biopharma Industrial Park, Telemedicine, Home Medical Care, Continuing Medical Education, Support Services Training Institutes, Construction & Maintenance, Unified Procurement, and Arabian Hospitality. The company also holds a 40% stake in Wareed Medical Company (laboratory and home healthcare services). This integrated model provides comprehensive healthcare services from hospital care to pharmaceuticals, medical education, support services, and home healthcare.
Differentiator
Problem solved
Functional benefit
Products and services
- Al Hammadi Hospital Group
Quantifiable outcome
- 18% revenue growth in 2022, reaching SAR 1,122 million from SAR 952 million in 2021.
- +6 more outcomes
Companies that use Al Hammadi Company For Development And Investment
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Al Hammadi Company For Development And Investment technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Al Hammadi Company For Development And Investment partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship, core and minor.
- A.C. Milan S.p.A.flagshipAl Hammadi Holding signed a multi-year strategic cooperation agreement with A.C. Milan S.p.A. at the MESIF Forum in Riyadh. The company and Al Hammadi Hospitals Group obtained exclusive rights as the Official Medical & Rehabilitation Partner of AC Milan in the Kingdom of Saudi Arabia. The SAR 54.5 million agreement spans 8 years ending June 30, 2033, focusing on developing medical, rehabilitation and performance-related collaboration between the club's medical experts and Al Hammadi's clinical facility in Riyadh. Expected to enhance Al Hammadi's corporate profile in advanced sports medicine and support specialized rehabilitation services development.
- Wareed Medical CompanycoreAl Hammadi Holding completed acquisition of a 40% stake in Wareed Medical Company (a limited liability company) for SAR 113 million. The transaction received No-Objection Certificate from the General Authority for Competition. Wareed Medical operates medical laboratory services and home healthcare services across 60 branches in KSA. Al Hammadi subscribed to a capital increase with investment paid in installments (SAR 20 million initial payment, remaining over 5 years). Wareed's revenues grew from SAR 1.2M (2022) to SAR 38.8M (2024). This acquisition expands Al Hammadi's integrated healthcare ecosystem outside hospitals.
- Sudair Pharmaceutical Company (SPC)coreAl Hammadi Holding owns 35% of Sudair Pharmaceutical Company (SPC), a leading Saudi-based pharmaceutical firm specializing in specialty care medications. SPC focuses on cancer-fighting medications and high-tech treatments for chronic and life-threatening diseases, addressing unmet medical needs in Saudi Arabia and the MENA region. SPC has submitted an IPO application to the Capital Market Authority for listing on the Main Market. SPC's business model includes international partnerships and dedication to quality and innovation, supporting KSA's 2030 vision for better health outcomes.
- BDO Dr. Muhammed Al-Amri & Co.minorBDO Dr. Muhammed Al-Amri & Co. was appointed as the independent auditor for Al Hammadi Holding for fiscal years 2025 and 2026 (fees of SAR 2,184,000 for 2025 and SAR 1,051,100 for 2024). The appointment was approved by the Ordinary General Assembly.
Scale indicators17 records
Recent moves9 records
Expansion highlights6 records
Al Hammadi Company For Development And Investment competitors and assessment
Company assessmentDirect peers
- Fakeeh Care Group: Saudi private hospital group (Dr. Soliman Fakeeh Hospital in Jeddah and others), expanding under Vision 2030 with multi-city hospitals. Direct peer in private hospital operations, premium positioning, and integrated medical services.
- Saudi German Health Group (SGH): One of the largest private hospital networks in Saudi Arabia (Batterjee family), operating hospitals in multiple cities. Direct peer in private acute-care hospital operations, serving similar patient mix and competing for the same Vision 2030 expansion awards.
- National Medical Care Company: Tadawul-listed Saudi private hospital operator running multiple facilities including in Riyadh. Directly comparable as a smaller publicly listed private hospital group serving similar insurance/MOH/direct-pay patient mix.
- Mouwasat Medical Services Company: Tadawul-listed private hospital operator headquartered in Dammam with facilities across KSA. Directly comparable as a publicly traded, MOH-contracted, multi-specialty private hospital group with similar revenue mix from insurance and government patients.
- Dallah Healthcare Holding Company: Riyadh-based Tadawul-listed private hospital and healthcare operator (Dallah Hospital, Dr. Mohammed Alfagih). Directly comparable as a competing Riyadh private hospital group with similar B2C/B2B and MOH contract revenue model.
- Dr. Sulaiman Al Habib Medical Services Group: Saudi Arabia's largest private hospital operator, Tadawul-listed, running 7+ hospitals and medical cities across KSA. Directly comparable as a publicly listed for-profit hospital operator serving MOH, insurance, and self-pay patients, with substantially larger scale than Al Hammadi.
Broad incumbents
- NMC Health (UAE): Pre-restructuring, NMC was the largest private healthcare operator in the GCC. Comparable as a regional integrated hospital, clinic and pharma operator with MENA-wide footprint; serves as a strategic reference for GCC private healthcare scale economics though not currently a direct Saudi competitor.
- King Faisal Specialist Hospital and Research Center: Saudi semi-governmental tertiary/quaternary hospital network operated by the government. Broad incumbent providing inpatient specialty care across KSA; competes for tertiary referrals and sets the standard for accreditation that private operators like Al Hammadi benchmark against.
Regional players
- Nahdi Medical Company: Saudi Arabia's largest retail pharmacy chain, with over 1,000 outlets across KSA and adjacent home-health distribution. Comparable as a Saudi healthcare retail/distribution network, primarily focused on pharmacy rather than inpatient care but overlapping with Al Hammadi's pharma distribution segment.
Emerging players
- Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO): Tadawul-listed Saudi pharmaceutical manufacturer and distributor. Comparable as a Saudi pharma operator in the same value chain as Al Hammadi's Pharmaceutical Services subsidiary and Sudair Pharma stake; overlaps on drug distribution and specialty medications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Al Hammadi Company For Development And Investment social profiles
Digital presenceAl Hammadi Company For Development And Investment financial estimates
Financial estimateRevenue estimate
Valuation estimate
Al Hammadi Company For Development And Investment leadership team
Management profileNumber of profiles
Profiles10 records
Al Hammadi Company For Development And Investment subsidiaries and ownership
Company hierarchySubsidiaries12 records
Al Hammadi Company For Development And Investment funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Al Hammadi Company For Development And Investment M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Al Hammadi Company For Development And Investment
What does Al Hammadi Company For Development And Investment do?
Al Hammadi Holding operates an integrated healthcare group headquartered in Riyadh, Saudi Arabia, delivering world-class inpatient and outpatient hospital services through its Al Hammadi Hospitals Group (Al Suwaidi and Al Nuzha hospitals, with Al Olaya under renovation and Al Narjis planned). The group also distributes pharmaceuticals, provides home medical care, telemedicine, medical training, hospital support services, and biopharma R&D across wholly-owned and affiliated subsidiaries.
Is Al Hammadi Company For Development And Investment a public or private company?
Al Hammadi Company For Development And Investment is a public company. It is classified as public and is currently operating.
When was Al Hammadi Company For Development And Investment founded?
Al Hammadi Company For Development And Investment was founded in 1985. It employs 1,001 to 5,000 people.
Where is Al Hammadi Company For Development And Investment based?
Al Hammadi Company For Development And Investment is headquartered in Riyadh, Saudi Arabia, in the Middle East region.
How does Al Hammadi Company For Development And Investment make money?
Five revenue lines are on record. Hospital / Medical Services are the primary driver. The others are pharmaceutical Products, medical Support Services, training & Education Services and sports Medicine Partnership (A.C. Milan).
Who are Al Hammadi Company For Development And Investment's main competitors?
Direct peers on record are Fakeeh Care Group, Saudi German Health Group (SGH), National Medical Care Company, Mouwasat Medical Services Company, Dallah Healthcare Holding Company and Dr. Sulaiman Al Habib Medical Services Group. Broad incumbents are NMC Health (UAE) and King Faisal Specialist Hospital and Research Center. Nahdi Medical Company is listed as a regional player. Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) is listed as an emerging player.
Does Al Hammadi Company For Development And Investment have an API?
No public API is recorded for Al Hammadi Company For Development And Investment.
What industry is Al Hammadi Company For Development And Investment in?
Al Hammadi Company For Development And Investment's product category is Hospital and Healthcare Services. Its primary akta.pro industry code is HLAFAAAF, Private/For-Profit Hospital Systems. Its NAICS code is 6221 and its SIC code is 8060.